title: Familial dysbetalipoproteinemia associated with apolipoprotein E3-Leiden in an extended multigeneration pedigree.
abstract: By the careful screening of familial dysbetalipoproteinemic (FD) patients, five probands showing heterozygosity for the APOE*3-Leiden allele were found. Genealogical studies revealed that these probands share common ancestry in the 17th century. In a group of 128 family members, spanning three generations, 37 additional heterozygous APOE*3-Leiden gene carriers were detected. Although with a variable degree of severity, all carriers exhibited characteristics of FD such as (a) elevated levels of cholesterol in the very low density lipoprotein (VLDL) and intermediate density lipoprotein (IDL) fractions, (b) elevated ratios of cholesterol levels in these density fractions over total plasma levels of triglycerides, and (c) strongly increased plasma levels of apolipoprotein E (apoE). Multiple linear regression analysis revealed that most of the variability in expression of FD in APOE*3-Leiden allele carriers can be explained by age. Body mass index showed a less significant influence on the expression of FD. Gender had no effect on the expression in E*3-Leiden allele carriers, nor did it influence the age of onset of FD. In the group of APOE*3-Leiden allele carriers, we found that the E*2 allele enhances the expression of FD, whereas the E*4 allele had the opposite effect. Isoelectric focusing of plasma and of isolated VLDL, IDL, and high density lipoprotein density fractions showed that in E*3-Leiden allele carriers the apoE3-Leiden variant largely predominates over its normal apoE counterpart, especially in the VLDL and IDL density fractions. We conclude that in APOE*3-Leiden allele carriers FD is dominantly inherited with a high rate of penetrance, i.e., the presence of normally functioning apoE molecules in the plasma does not prevent the age-related expression of this disease.
authors.affiliation: Institute of Ageing and Vascular Research, Netherlands Organization for Applied Scientific Research, Leiden.
authors.forename: P
authors.initials: P
authors.lastname: de Knijff
authors.forename: A M
authors.initials: AM
authors.lastname: van den Maagdenberg
authors.forename: A F
authors.initials: AF
authors.lastname: Stalenhoef
authors.forename: J A
authors.initials: JA
authors.lastname: Leuven
authors.forename: P N
authors.initials: PN
authors.lastname: Demacker
authors.forename: L P
authors.initials: LP
authors.lastname: Kuyt
authors.forename: R R
authors.initials: RR
authors.lastname: Frants
authors.forename: L M
authors.initials: LM
authors.lastname: Havekes
mesh_terms: D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D000483:Alleles; D053318:Apolipoprotein E3; D001057:Apolipoproteins E / Q000235:genetics*; D001835:Body Weight; D002784:Cholesterol / Q000032:analysis; D015243:Cholesterol, VLDL / Q000032:analysis; D005260:Female; D006580:Genetic Carrier Screening; D006579:Heterozygote; D006801:Humans; D006952:Hyperlipoproteinemia Type III / Q000235:genetics*; D008074:Lipoproteins / Q000032:analysis; D008297:Male; D008875:Middle Aged; D010375:Pedigree; D012737:Sex Factors
chemical_list: D053318:Apolipoprotein E3; D001057:Apolipoproteins E; D015243:Cholesterol, VLDL; D008074:Lipoproteins; C052720:apolipoprotein E3 (Leidein); C030104:lipoprotein cholesterol; D002784:Cholesterol